AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03905863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natrox® Oxygen Wound Therapy
Description: A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
Study NCT04337411 — intervention group
Intervention type: OTHER
Intervention: Follow-up assessments
Description: Longitudinal evaluation of recovery
Study NCT01300182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Description: The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
Study NCT01300182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional post-operative physical therapy exercises and rehabilitation.
Study NCT04176185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual allergy immunological tablet
Description: For daily administration (1 tablet per day)
Study NCT04176185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For daily administration (1 tablet per day)
Study NCT02601924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% Benzocain (Master-Dent, Monroe, NC)
Description: Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
Study NCT03480724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Rift VRA
Description: Intervention was randomized and shuffled.
Study NCT02402998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg/daily.
Study NCT02601924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical pressure massage
Description: Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
Study NCT00568555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Naltrexone
Description: 3-4.5mg Naltrexone once daily
Study NCT00568555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Naltrexone
Description: 3-4.5mg Naltrexone once daily
Study NCT00568555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - sugar pill
Description: Placebo pill once daily
Study NCT00568555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar pill
Description: Placebo pill once daily
Study NCT04357457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almitrine
Description: Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
Study NCT04357457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous glucose 5% during 5 days
Study NCT02354703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (0.33 mg) bid+ BBCET counseling
Study NCT02354703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + BBCET counseling
Study NCT02010151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAD-CPR
Description: When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
Study NCT00380042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cortical Stimulation
Description: Cortical stimulation of prefrontal cortex
Study NCT00380042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham stimulation
Study NCT02804841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol -Vitamin D3
Study NCT02804841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -gel capsule containing no vitamin D.
Study NCT01600625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral minocycline hydrochloride treatment
Description: Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Study NCT03495778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 50.5 Test Granola
Study NCT03495778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.3 Control Granola
Study NCT03160794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]DCFPyL PET/MRI scan
Description: PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
Study NCT03160794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT02161692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: High dose carboplatin
Study NCT00700167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine
Description: The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.
Study NCT02888496 — intervention group
Intervention type: DRUG
Intervention: tocilizumab
Description: 3 monthly IV infusions in PMR patients
Study NCT00375401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment A
Description: Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
Study NCT00375401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
Study NCT00375401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
Study NCT02678559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tee measurement
Study NCT02678559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flotrac measurement
Study NCT02678559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clearsight measurement
Study NCT01645943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiogram
Description: Routine coronary angiogram and revascularization if indicated
Study NCT03433612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic Intercristal Line Technique
Description: Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique.
Study NCT03433612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Novel SAIL Technique
Description: Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique.
Study NCT04084119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive abdominal exercise
Description: Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
Study NCT04084119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general strengthening exercise
Description: Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
Study NCT01906944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
Study NCT01906944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone is a long-acting synthetic corticosteroid.
Study NCT01492998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guggulsterone, a natural FXR antagonist.
Description: Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
Study NCT00331500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Study NCT00331500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT04226794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a-tDCS
Description: Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).
Study NCT04226794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions
Study NCT04226794 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: a-tDCS and nutritional counseling
Description: a-tDCS + Nutritional Counseling
Study NCT04226794 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: s-tDCS and nutritional counseling
Description: s-tDCS + Nutritional Counseling
Study NCT04508660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: BID application
Study NCT04270760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olpasiran
Description: Dose 1 Dose 2 Dose 3 Dose 4
Study NCT04270760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 5
Study NCT01002092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
Study NCT01002092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
Study NCT01002092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
Study NCT05855512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Educational Intervention
Description: Nursing Educational Intervention
Study NCT04415073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNDX-6352
Description: SNDX-6352
Study NCT04415073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT01076465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease management program
Description: 1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
Study NCT01076465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT03329456 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Minimum effective volume
Study NCT04520529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biologic Samples
Description: * An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.
Study NCT04732390 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae block with bupivacaine
Description: Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
Study NCT01992809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
Study NCT03242330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal implant
Description: Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
Study NCT04732390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block with bupivacaine and magnesium sulphate
Description: Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
Study NCT02183740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted educational program
Study NCT05606029 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy, extended cholecystectomy
Description: Cholecystectomy and histopathological evaluation
Study NCT03242330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subperiosteal implant
Description: Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
Study NCT01099202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit (epoetin alfa)
Description: Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
Study NCT00740610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
Study NCT03546855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg/d po,28 days as one cycle
Study NCT00664248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-110
Description: Topical application for 12 weeks
Study NCT00664248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Topical application for 12 weeks
Study NCT00664248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide
Description: Topical application for 12 weeks
Study NCT00740610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily
Study NCT03820440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EEOT)
Description: The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
Study NCT03820440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung recruitment manovre (LRM)
Description: The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
Study NCT00664248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study NCT00200850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: House Dust Mite SLIT
Description: low dose SLIT 143 Allergen Units(AU)/ml daily
Study NCT00200850 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose SLIT
Description: House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
Study NCT00200850 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT
Description: Placebo SLIT daily
Study NCT01864408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice counseling
Study NCT01864408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad).
Description: After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling.
Study NCT00700180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle
Study NCT00700180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle
Study NCT00700180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy
Description: As prescribed
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
Study NCT04221477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study NCT00799851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variceal band ligation
Study NCT00799851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate injection
Description: cyanoacrylate injection
Study NCT04235413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-Time Incentives Group
Description: The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
Study NCT02226445 — intervention group
Intervention type: OTHER
Intervention: Combined ADHD medication and psychosocial counseling
Description: The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine.